Sign inJoin waitlistJoin the waitlist

Abdulraheem Yacoub

Professor, Hematologic Malignancies and Cellular Therapeutics · University of Kansas School of Medicine

Credentials: · · · · ·

History

University of Kansas School of Medicine
Present

Hematology and Medical Oncology
University of Arkansas for Medical Sciences
2007–2010
University of Saint Louis
2004–2007
King Hussein Cancer Center
2003–2004
University of Jordan Faculty of Medicine
1999–2003

Research

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
Journal of Clinical Oncology · 2020 · 242 citations
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Blood · 2019 · First of 34 authors · 149 citations
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
Blood · 2022 · 122 citations

Ruben Mesa
30 papers
John Mascarenhas
25 papers
RR
Raajit Rampal
14 papers
Ronald Hoffman
13 papers
Aaron Gerds
12 papers
Prithviraj Bose
10 papers
AK
Andrew Kuykendall
9 papers
Stephen Oh
9 papers
Casey O'Connell
8 papers
Ghaith Abu-Zeinah
8 papers
Nikolai Podoltsev
8 papers · 4 as a resident
Jason Gotlib
7 papers

Clinical trials

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
Principal investigator · Recruiting · Early phase 1
University of Kansas Medical Center
2025–2026
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Study chair · Not yet recruiting · Phase 2
John Mascarenhas
2026–2030
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027